Send to a Friend Share

BofA/Merrill Lynch Upgrades Regeneron Pharma (REGN) to Buy

January 30, 2012 8:09 AM EST
REGN Hot Sheet
Rating Summary:
    9 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 16 | Down: 7 | New: 23
BofA/Merrill Lynch upgraded Regeneron Pharma (NASDAQ: REGN) from Neutral to Buy.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $85.54 yesterday, with a 52 week range of $33.36-$86.15.


Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!

You May Also Be Interested In


Related Categories

Upgrades

Related Entities

Merrill Lynch, Bank of America

Add Your Comment





Follow StreetInsider.com On Twitter